Showing results (11-20 of 103) with videos related to

Sort By:
Pageof 11
Journal of Cancer Research and Clinical Oncology|January 1, 1991
Evaluation of CA19-9 serum levels for monitoring disease activity during chemotherapy of pancreatic adenocarcinomaD J Bac, T C Kok, A van der Gaast, et al.
Seminars in Oncology|January 14, 1998
A phase I dose finding study of a biweekly schedule of a fixed dose of cisplatin with increasing doses of paclitaxel in patients with advanced esophageal cancerA van der Gaast, T C Kok, R Vos, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1993
Correlation between changes in the tumour markers CA-M26 and CA-M29 and standard response evaluation in patients with metastatic breast cancerA van der Gaast, C Hulshof, T C Kok, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 1, 1994
Phase II study of carboplatin and etoposide as a first line regimen in patients with metastatic breast cancerA van der Gaast, M Bontenbal, A S Planting, et al.
European Journal of Cancer (Oxford, England : 1990)|October 1, 1995
Disease monitoring by the tumour markers cyfra 21.1 and TPA in patients with non-small cell lung cancerA van der Gaast, T C Kok, G S Kho, et al.
British Journal of Cancer|June 11, 1999
Phase I study of a biweekly schedule of a fixed dose of cisplatin with increasing doses of paclitaxel in patients with advanced oesophageal cancerA van der Gaast, T C Kok, L Kerkhofs, et al.
British Journal of Cancer|March 1, 1994
Evaluation of a new tumour marker in patients with non-small-cell lung cancer: Cyfra 21.1A van der Gaast, C H Schoenmakers, T C Kok, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1994
Prognostic significance of tissue polypeptide-specific antigen (TPS) in patients with advanced non-small cell lung cancerA van der Gaast, C H Schoenmakers, T C Kok, et al.
Seminars in Oncology|August 1, 1997
Introduction to the treatment of lung cancerT A Splinter
Nederlands Tijdschrift Voor Geneeskunde|May 31, 1997
[The changing role of chemotherapy in the treatment of non-small cell lung carcinoma stage III]T A Splinter
Pageof 11